Wayinia Lifesciences Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.10 M
- Company Age 9 Year, 4 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 1.70 M
- Revenue Growth 104.06%
- Profit Growth 417.45%
- Ebitda 347.46%
- Net Worth 156.12%
- Total Assets 30.06%
About Wayinia Lifesciences
Wayinia Lifesciences Private Limited (WLPL) is a registered startup operating as a Private Limited Indian Non-Government Company incorporated in India on 17 September 2015 (Nine years and four months 14 days old ). Its registered office is in Gurugram, Haryana, India.
The Corporate was formerly known as Wayinia Lifesciences Opc Private Limited. The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹1.70 M.
Rajan Chaudhary and Shivam Sahu serve as directors at the Company.
Company Details
- Location
Gurugram, Haryana, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media
Corporate Identity Details
- CIN/LLPIN
U93000HR2015PTC056697
- Company No.
056697
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
17 Sep 2015
- Date of AGM
17 Jul 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Who are the key members and board of directors at Wayinia Lifesciences?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Shivam Sahu  | Director | 19-Mar-2020 | Current |
| Rajan Chaudhary | Director | 17-Sep-2015 | Current |
Financial Performance of Wayinia Lifesciences.
Wayinia Lifesciences Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 104.06% increase. The company also saw a substantial improvement in profitability, with a 417.45% increase in profit. The company's net worth Soared by an impressive increase of 156.12%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Wayinia Lifesciences?
In 2022, Wayinia Lifesciences had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹1.70 M
₹0
Charges Breakdown by Lending Institutions
- Hdfc Bank Limited : 0.17 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 17 Feb 2023 | Hdfc Bank Limited | ₹1.70 M | Open |
How Many Employees Work at Wayinia Lifesciences?
Unlock and access historical data on people associated with Wayinia Lifesciences, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Wayinia Lifesciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Wayinia Lifesciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
